Optimal treatment targets for lupus nephritis using per-protocol repeat kidney biopsy findings at 2 years and clinical data up to 5 years: a single-center observational study.

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Chronic Disease Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.1177/20406223241289074
Hidetoshi Kagawa, Ryutaro Yamanaka, Ai Matsubara, Tatsuyuki Inoue, Reika Hayashi, Natsuki Kubota, Tsutomu Hiromasa
{"title":"Optimal treatment targets for lupus nephritis using per-protocol repeat kidney biopsy findings at 2 years and clinical data up to 5 years: a single-center observational study.","authors":"Hidetoshi Kagawa, Ryutaro Yamanaka, Ai Matsubara, Tatsuyuki Inoue, Reika Hayashi, Natsuki Kubota, Tsutomu Hiromasa","doi":"10.1177/20406223241289074","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The criteria for remission in both clinical and pathological contexts for lupus nephritis (LN) remain controversial.</p><p><strong>Objectives: </strong>To identify optimal short-term goals (remission criteria) for LN predicting long-term success at 5 years, using repeat kidney biopsy (Biopsy 2) and clinical data.</p><p><strong>Design: </strong>Single-center observational study.</p><p><strong>Methods: </strong>Twenty-three consecutive LN patients undergoing Biopsy 2 2 years post-induction therapy were evaluated. Two ideal long-term goals at 5 years were defined as: \"A,\" Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) = 0 and prednisolone (PSL) ⩽5 mg/day, and \"B,\" proteinuria ⩽0.2 g/day with a normal serum creatinine level and PSL ⩽5 mg/day. Histologically, the electron-dense deposit (EDD) score grades immune deposits based on their intensity, amount, and location. A score of ⩽1 was defined as \"electron microscopy remission (ER).\"</p><p><strong>Results: </strong>Conventional renal indices failed to predict long-term goals. The short-term goals with an accuracy (area under the curve: 95% confidence interval) of ⩾0.8 predicted long-term goals: \"A at 5 years\" (A-5y), A-2y (0.91: 0.79-1.00), DORIS-R-2y (0.87: 0.72-1.00), EDD score (0.85: 0.70-1.00), B-2y (0.83: 0.66-0.99), and SLEDAI-R-2y (0.82: 0.66-0.98) as well as \"B at 5 years\" (B-5y), A-2y (0.87: 0.73-1.00), B-2y (0.87: 0.73-1.00), EDD score (0.85: 0.69-1.00), and DORIS-R-2y (0.83: 0.67-0.99). EDD scores predicted A-5y, B-5y, and PSL dose at 5 years in proportion to the score. The clinical and histological goals aligned.</p><p><strong>Conclusion: </strong>The best predictive short-term goal was A-2y. Concordance between clinical remission (A-2y, B-2y, and DORIS-R-2y) and histological remission (ER) at 2 years suggests optimal short-term goals for LN.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"15 ","pages":"20406223241289074"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483839/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223241289074","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The criteria for remission in both clinical and pathological contexts for lupus nephritis (LN) remain controversial.

Objectives: To identify optimal short-term goals (remission criteria) for LN predicting long-term success at 5 years, using repeat kidney biopsy (Biopsy 2) and clinical data.

Design: Single-center observational study.

Methods: Twenty-three consecutive LN patients undergoing Biopsy 2 2 years post-induction therapy were evaluated. Two ideal long-term goals at 5 years were defined as: "A," Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) = 0 and prednisolone (PSL) ⩽5 mg/day, and "B," proteinuria ⩽0.2 g/day with a normal serum creatinine level and PSL ⩽5 mg/day. Histologically, the electron-dense deposit (EDD) score grades immune deposits based on their intensity, amount, and location. A score of ⩽1 was defined as "electron microscopy remission (ER)."

Results: Conventional renal indices failed to predict long-term goals. The short-term goals with an accuracy (area under the curve: 95% confidence interval) of ⩾0.8 predicted long-term goals: "A at 5 years" (A-5y), A-2y (0.91: 0.79-1.00), DORIS-R-2y (0.87: 0.72-1.00), EDD score (0.85: 0.70-1.00), B-2y (0.83: 0.66-0.99), and SLEDAI-R-2y (0.82: 0.66-0.98) as well as "B at 5 years" (B-5y), A-2y (0.87: 0.73-1.00), B-2y (0.87: 0.73-1.00), EDD score (0.85: 0.69-1.00), and DORIS-R-2y (0.83: 0.67-0.99). EDD scores predicted A-5y, B-5y, and PSL dose at 5 years in proportion to the score. The clinical and histological goals aligned.

Conclusion: The best predictive short-term goal was A-2y. Concordance between clinical remission (A-2y, B-2y, and DORIS-R-2y) and histological remission (ER) at 2 years suggests optimal short-term goals for LN.

利用按协议重复肾活检结果(2 年)和临床数据(5 年)确定狼疮肾炎的最佳治疗目标:一项单中心观察性研究。
背景:狼疮性肾炎(LN)的临床和病理缓解标准仍存在争议:狼疮性肾炎(LN)的临床和病理缓解标准仍存在争议:设计:单中心观察性研究:设计:单中心观察性研究:方法:对接受诱导治疗两年后再次活检的 23 名 LN 患者进行评估。5年后的两个理想长期目标被定义为A",系统性红斑狼疮疾病活动指数 2000 (SLEDAI-2K) = 0,泼尼松龙 (PSL) ⩽5 mg/天;"B",蛋白尿 ⩽0.2 g/天,血清肌酐水平正常,PSL ⩽5 mg/天。组织学上,电子致密沉积物(EDD)评分根据免疫沉积物的强度、数量和位置进行分级。得分⩽1被定义为 "电子显微镜缓解(ER)":传统的肾脏指数无法预测长期目标。准确率(曲线下面积:95% 置信区间)为 ⩾0.8 的短期目标可预测长期目标:"5年后达到A级"(A-5y)、A-2y(0.91:0.79-1.00)、DORIS-R-2y(0.87:0.72-1.00)、EDD评分(0.85:0.70-1.00)、B-2y(0.83:0.66-0.99)和SLEDAI-R-2y(0.82:0.66-0.98)以及 "5 岁时为 B"(B-5y)、A-2y(0.87:0.73-1.00)、B-2y(0.87:0.73-1.00)、EDD 分数(0.85:0.69-1.00)和 DORIS-R-2y (0.83:0.67-0.99)。EDD 评分可预测 5 年后的 A-5y、B-5y 和 PSL 剂量,其比例与评分成正比。临床和组织学目标一致:结论:预测性最好的短期目标是A-2y。临床缓解(A-2y、B-2y 和 DORIS-R-2y)与 2 年后组织学缓解(ER)之间的一致性表明,LN 的短期目标是最佳的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)
CiteScore
6.20
自引率
0.00%
发文量
108
审稿时长
12 weeks
期刊介绍: Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信